Designed to kill: novel menin-MLL inhibitors target MLL-rearranged leukemia.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The interaction between menin and oncogenic mixed lineage leukemia (MLL) fusion proteins is required for leukemic transformation and may represent a therapeutic opportunity. In this issue of Cancer Cell, Borkin and colleagues describe the development of highly potent small-molecule inhibitors of this interaction that reverse the leukemic phenotype and prolong survival in murine models of MLL-rearranged leukemia.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancer Cell

Title: Cancer cell

Publisher: Elsevier BV

ISSN (Electronic): 1878-3686

ISSN (Print): 1535-6108

Publication date (Electronic): Apr 13 2015

Volume: 27

Issue: 4

Affiliations

[1 ] Cancer Biology and Genetics Program and Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

[2 ] Cancer Biology and Genetics Program and Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: armstros@mskcc.org.

Article

Publisher Item ID: S1535-6108(15)00100-2

DOI: 10.1016/j.ccell.2015.03.012

PubMed ID: 25873167

SO-VID: bf3767f0-4027-4e56-91d1-71b422c03291

History

Data availability:

Comments

Comment on this article

scite_

Cited by 11

See all cited by

- Version 1